Akamai Technologies, Inc. (AKAM)

Akamai Technologies, Inc. (AKAM) is trading near the bottom of its 52-week range after a steep slide, and the stock is in the middle of a sharp reassessment. The price sits 3.77% above its 52-week low of $77.37 and well below its 50-day and 200-day moving averages ($101.01 and $112.26), while the 20-day average has only recently started to sit above the price. Analysts remain constructive: 15 of 24 rate the stock Buy or Strong Buy, and the median target is $150.00. The gap between that view and the price is the central question for investors now.

Akamai has beaten EPS estimates in each of the last eight reports, yet the share price has moved against the beats more often than not. In the first session after the February 19, 2026 report, the stock fell 14.07% despite a 5.14% beat. In five of the eight reports that were followed by a beat, the share price was lower in the first session. The most recent report, on November 5, 2026, brought adjusted EPS of $1.77 against an estimate of $1.67, a 5.99% beat, and the stock rose 6.74% the next session. That bounce has not yet changed the direction of the trend.

Return on equity of 7.85% is below the sector median of 13.4%, and debt-to-equity stands at 1.84. These figures explain much of why the stock has been de-rated. Analysts still expect revenue to grow 5.9% this fiscal year, so the business is expanding, but at a pace that does not match the wider sector.

At a trailing P/E of 31.24, Akamai sits 11.0% below the sector median of 35.1, which the Peer Benchmarking card puts broadly in line with peers. The price-to-sales ratio of 2.63 is 65.4% below the sector median of 7.6. On the other hand, the stock is valued on lower growth, so the discount reflects the slower top line rather than a mispricing alone.

Of 24 analysts with a current rating, 15 rate the stock Buy or Strong Buy, 8 hold it and only 1 sells. Three months ago, 15 of 25 ratings were Buy. Recent actions include Raymond James upgrading to Strong Buy from Outperform on October 20, 2026, and Morgan Stanley keeping its Overweight rating on November 2, 2026. Over the last 18 months, insiders sold $19.7M of stock across 34 sales and bought $3.8M across 2 open-market purchases. Insider sales are often planned in advance or made to cover tax on vesting shares, so they carry less weight than open-market buying.

The base case is that AKAM stays under pressure until the trend stops making lower lows. For the price to repair its trend, it has to climb back through the 20-day EMA at $91.05 and then the 50-day SMA at $101.01, and hold above them. Analysts expect revenue to rise 5.9% this fiscal year and EPS to grow 6.0% next year, after an expected 8.2% decline this year, so the operating story is steadier than the share price suggests. A break below the 52-week low of $77.37 would signal that the sell-off is still gathering pace, and the analysts' median target of $150.00 would look distant. A sustained move back above the 200-day SMA at $112.26 would show that the market is starting to price in the earnings beats and the Buy consensus. CleaRank's rating of Sell reflects the weight of the price trend and momentum, not a view on the business.

Support sits first at the 52-week low of $77.37, which the price is currently testing; a fall through it would open new ground with no prior trading floor. Resistance comes first at the 20-day EMA of $91.05, then the 50-day SMA at $101.01, and the 200-day SMA at $112.26. The 52-week high of $165.45 is far above, and a rise to it would need a full reversal of the trend.